The IL11 Knockout KYSE-150 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the IL11 gene in the human esophageal squamous cell carcinoma (ESCC) cell line KYSE-150. This product provides a heterogeneous pool of IL11-deficient cells, offering a robust loss-of-function model without clonal selection bias. The polyclonal format is suitable for studying IL11-dependent processes in a clinically relevant ESCC context. Genomic editing is validated to ensure IL11 locus disruption, enabling reproducible functional investigations.
KYSE-150 is a well-characterized human ESCC cell line derived from a poorly differentiated esophageal squamous cell carcinoma. It retains aggressive growth properties, metastatic potential, and epithelial morphology, making it a valuable model for esophageal cancer research. The cell line is amenable to genetic manipulation, drug testing, and xenograft studies, thus providing an appropriate host for CRISPR-mediated knockout generation to interrogate gene function in oncogenesis.
Interleukin-11 (IL11) is a pleiotropic cytokine that signals via a receptor complex of IL11RA and gp130, activating JAK1/JAK2 and downstream STAT3, MAPK/ERK, and PI3K-AKT pathways. Upstream inducers include TGF-??, IL-1, TNF-??, and hypoxia, acting through NF-??B and AP-1. Activated STAT3 promotes expression of collagen genes, TIMP1, CTGF, BCL-2, and survivin, while inducing SOCS3 feedback. These signaling cascades place IL11 at the intersection of proliferation, survival, fibrosis, and inflammation.
In KYSE-150 cells, autocrine IL11 signaling enhances proliferation, invasion, and chemoresistance primarily via STAT3-driven transcriptional programs. Disruption of IL11 expression in this ESCC background abrogates this autocrine loop, allowing dissection of IL11??s specific contributions to malignant phenotypes. Additionally, IL11??s profibrotic functions, in crosstalk with TGF-??, can modulate the tumor microenvironment, making this knockout model useful for studying tumor?Cstroma interactions and fibrosis-related cancer progression.
This knockout model supports diverse applications: western blotting and phospho-arrays to assess STAT3, ERK1/2, and AKT activation; RT-qPCR and RNA-seq for transcriptomic profiling; MTT/CCK-8 proliferation, transwell migration/invasion, colony formation, and flow cytometry-based apoptosis and cell cycle analyses. In vivo xenograft studies can evaluate metastatic potential and drug responses. Co-culture experiments enable investigation of IL11??s role in shaping the tumor microenvironment. For further details, contact Ascent Research.
